VIP-10 Overview
Mechanism of Action
Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide acting as potent vasodilator and immunomodulator. It binds VPAC1/VPAC2 receptors, reducing pro-inflammatory cytokines (TNF-α, IL-6, IL-12), shifting immune balance from Th1 to Th2, and promoting regulatory T cell activity. Also supports pulmonary function by reducing pulmonary artery pressure.
~1–2 minutes (tissue effects persist longer)
Timing
Spaced throughout day if intranasal; morning if SQ
Injection Site
Subcutaneous or intranasal
Food
No restrictions
Common Stacks
- LL-37 — Antimicrobial + immune modulation
- BPC-157 — Tissue repair synergy
- Thymosin Alpha-1 — Immune restoration
VIP-10 Dosing Protocol
Standard Protocol
4–8 weeks50–100 mcg SQ daily
Can also be intranasal.
CIRS Protocol
As prescribed50 mcg intranasal 4x daily
Per Shoemaker protocol for chronic inflammatory response syndrome.
VIP-10 Expected Timeline
Week 1–2
Reduced inflammatory symptoms
Week 3–4
Improved respiratory function
Month 1–2
Sustained immune modulation
VIP-10 Side Effects
Nasal congestion (intranasal)
Diarrhea
Facial flushing
Hypotension (rare)
VIP-10 Research Studies
VIP as a new drug for inflammatory disorders
Delgado M, Pozo D, Ganea D — Mol Med (2004)
Comprehensive review of VIP's anti-inflammatory and immunomodulatory mechanisms across multiple inflammatory disease models.
PubMed: 15014400VIP-10 FAQ
Why is VIP used for mold illness/CIRS?
Dr. Shoemaker’s CIRS protocol uses intranasal VIP to address dysregulated inflammation. VIP reduces pulmonary artery pressure, normalizes C4a, TGF-β1, and VEGF.
Why is VIP’s half-life so short?
Rapidly degraded by dipeptidyl peptidase IV. However, receptor binding triggers cAMP cascades that persist well beyond plasma clearance.